Drug intelligence / Profile preview

EPS 226

Development stage: Preclinical
Lead developer: Epsilogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EPS 226 is a preclinical-stage monoclonal antibody of the IgE isotype targeting the Human Epidermal Growth Factor Receptor 2 (HER2). Developed by Epsilogen, it is being investigated for the treatment of HER2-positive breast cancer. Unlike traditional IgG-based antibodies, EPS 226 utilizes the IgE isotype to leverage the unique properties of the IgE-mediated immune response, which includes high-affinity binding to FcεRI receptors on effector cells like mast cells, basophils, and eosinophils. This approach aims to enhance anti-tumor activity and potentially overcome resistance mechanisms associated with IgG-based therapies.

Targets

FCER1 (Fc epsilon RI receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on EPS 226.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPS 226.

Explore the full profile